Author Correction: Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Author Correction: Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial ; volume:14 ; number:1 ; day:12 ; month:12 ; year:2023 ; pages:1 ; date:12.2023
Nature Communications ; 14, Heft 1 (12.12.2023), 1, 12.2023
- Urheber
-
Buisseret, Laurence
Loirat, Delphine
Aftimos, Philippe
Maurer, Christian
Punie, Kevin
Debien, Véronique
Kristanto, Paulus
Eiger, Daniel
Goncalves, Anthony
Ghiringhelli, François
Taylor, Donatienne
Clatot, Florent
Mooter, Tom Van den
Ferrero, Jean-Marc
Bonnefoi, Hervé
Canon, Jean-Luc
Duhoux, Francois P.
Mansi, Laura
Poncin, Renaud
Barthélémy, Philippe
Isambert, Nicolas
Denis, Zoë
Catteau, Xavier
Salgado, Roberto
Agostinetto, Elisa
Azambuja, Evandro de
Rothé, Françoise
Craciun, Ligia
Venet, David
Romano, Emanuela
Stagg, John
Paesmans, Marianne
Larsimont, Denis
Sotiriou, Christos
Ignatiadis, Michail
Piccart-Gebhart, Martine
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41467-023-44071-8
- URN
-
urn:nbn:de:101:1-2024022713143246691582
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:48 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Buisseret, Laurence
- Loirat, Delphine
- Aftimos, Philippe
- Maurer, Christian
- Punie, Kevin
- Debien, Véronique
- Kristanto, Paulus
- Eiger, Daniel
- Goncalves, Anthony
- Ghiringhelli, François
- Taylor, Donatienne
- Clatot, Florent
- Mooter, Tom Van den
- Ferrero, Jean-Marc
- Bonnefoi, Hervé
- Canon, Jean-Luc
- Duhoux, Francois P.
- Mansi, Laura
- Poncin, Renaud
- Barthélémy, Philippe
- Isambert, Nicolas
- Denis, Zoë
- Catteau, Xavier
- Salgado, Roberto
- Agostinetto, Elisa
- Azambuja, Evandro de
- Rothé, Françoise
- Craciun, Ligia
- Venet, David
- Romano, Emanuela
- Stagg, John
- Paesmans, Marianne
- Larsimont, Denis
- Sotiriou, Christos
- Ignatiadis, Michail
- Piccart-Gebhart, Martine
- SpringerLink (Online service)
Ähnliche Objekte (12)
Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial
Identification of characteristics predictive of long-term survival with durvalumab or durvalumab plus tremelimumab in metastatic urothelial carcinoma
A phase I study to assess afatinib in combination with carboplatin or with carboplatin plus paclitaxel in patients with advanced solid tumors
A phase II study of carboplatin and etoposide plus durvalumab for previously untreated extensive-stage small-cell lung cancer (ES-SCLC) patients with a poor performance status (PS): NEJ045A study protocol
Chemotherapy-induced nausea and vomiting (CINV) with carboplatin plus pemetrexed or carboplatin plus paclitaxel in patients with lung cancer: a propensity score-matched analysis
A phase 2 study of AZD4635 in combination with durvalumab or oleclumab in patients with metastatic castration-resistant prostate cancer
Genetic dynamics in untreated CLL patients with either stable or progressive disease: a longitudinal study
Efficacy, safety and biomarker analysis of durvalumab in patients with mismatch-repair deficient or microsatellite instability-high solid tumours
Comparison of neoadjuvant chemoradiation with carboplatin/ paclitaxel or cisplatin/ 5-fluoruracil in patients with squamous cell carcinoma of the esophagus
Phase Ib Dose-Finding Study of Varlitinib Combined with Weekly Paclitaxel With or Without Carboplatin ± Trastuzumab in Advanced Solid Tumors
The effects of taurolidine alone and in combination with doxorubicin or carboplatin in canine osteosarcoma in vitro
Arzneimittel Profil Durvalumab
Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial
Identification of characteristics predictive of long-term survival with durvalumab or durvalumab plus tremelimumab in metastatic urothelial carcinoma
A phase I study to assess afatinib in combination with carboplatin or with carboplatin plus paclitaxel in patients with advanced solid tumors
A phase II study of carboplatin and etoposide plus durvalumab for previously untreated extensive-stage small-cell lung cancer (ES-SCLC) patients with a poor performance status (PS): NEJ045A study protocol
Chemotherapy-induced nausea and vomiting (CINV) with carboplatin plus pemetrexed or carboplatin plus paclitaxel in patients with lung cancer: a propensity score-matched analysis
A phase 2 study of AZD4635 in combination with durvalumab or oleclumab in patients with metastatic castration-resistant prostate cancer
Genetic dynamics in untreated CLL patients with either stable or progressive disease: a longitudinal study
Efficacy, safety and biomarker analysis of durvalumab in patients with mismatch-repair deficient or microsatellite instability-high solid tumours
Comparison of neoadjuvant chemoradiation with carboplatin/ paclitaxel or cisplatin/ 5-fluoruracil in patients with squamous cell carcinoma of the esophagus
Phase Ib Dose-Finding Study of Varlitinib Combined with Weekly Paclitaxel With or Without Carboplatin ± Trastuzumab in Advanced Solid Tumors
The effects of taurolidine alone and in combination with doxorubicin or carboplatin in canine osteosarcoma in vitro
Arzneimittel Profil Durvalumab
Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial
Identification of characteristics predictive of long-term survival with durvalumab or durvalumab plus tremelimumab in metastatic urothelial carcinoma
A phase I study to assess afatinib in combination with carboplatin or with carboplatin plus paclitaxel in patients with advanced solid tumors
A phase II study of carboplatin and etoposide plus durvalumab for previously untreated extensive-stage small-cell lung cancer (ES-SCLC) patients with a poor performance status (PS): NEJ045A study protocol
Chemotherapy-induced nausea and vomiting (CINV) with carboplatin plus pemetrexed or carboplatin plus paclitaxel in patients with lung cancer: a propensity score-matched analysis
A phase 2 study of AZD4635 in combination with durvalumab or oleclumab in patients with metastatic castration-resistant prostate cancer
Genetic dynamics in untreated CLL patients with either stable or progressive disease: a longitudinal study
Efficacy, safety and biomarker analysis of durvalumab in patients with mismatch-repair deficient or microsatellite instability-high solid tumours
Comparison of neoadjuvant chemoradiation with carboplatin/ paclitaxel or cisplatin/ 5-fluoruracil in patients with squamous cell carcinoma of the esophagus
Phase Ib Dose-Finding Study of Varlitinib Combined with Weekly Paclitaxel With or Without Carboplatin ± Trastuzumab in Advanced Solid Tumors
The effects of taurolidine alone and in combination with doxorubicin or carboplatin in canine osteosarcoma in vitro